Search

Hintergrund und Stand (inter)nationaler Forschung: Registerbasierte Daten gewinnen zunehmend an Bedeutung für die Evidenzgenerierung und die Beurteilung der Versorgungsqualität in der Routineversorgung. TREATgermany erfasst als deutsches Neurodermitisregister seit 2016 klinische und patientenberichtete [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Hintergrund und Stand (inter)nationaler Forschung: TREATgermany erfasst als deutsches Neurodermitis Register seit 2016 Daten von Patient:innen mit moderater bis schwerer Atopischer Dermatitis (AD). Als chronische Hauterkrankung geht die AD mit individuellen Krankheitsverläufen einher. Zur Behandlung [zum vollständigen Text gelangen Sie über die oben angegebene URL]

The German atopic eczema (AE)-registry TREATgermany is a non-interventional multicenter patient cohort study for adult patients with currently moderate-to-severe disease activity or current/previous anti-inflammatory systemic treatment.1,2 Dupilumab has demonstrated to be an effective treatment for patients with moderate-to-severe AE in clinical trials.3-5 Real world evidence is now needed to evaluate its effectiveness and safety in routine care.

Background A two-fold risk increase to develop basal cell carcinoma was seen in outdoor workers exposed to high solar UV radiation compared to controls. However, there is an ongoing discussion whether histopathological subtype, tumor localization and Fitzpatrick phototype may influence the risk estimates. Objectives To evaluate the influence of histological subtype, tumor localization and Fitzpatrick phototype on the risk to develop basal cell carcinoma in highly UV-exposed cases and controls compared to those with moderate or low solar UV exposure. Methods Six hundred forty-three participants suffering from incident basal cell carcinoma in commonly sun-exposed anatomic sites (capillitium, face, lip, neck, dorsum of the hands, forearms outside, décolleté) of a population-based, case-control, multicenter study performed from 2013 to 2015 in Germany were matched to controls without skin cancer. Multivariate logistic regression analysis was conducted stratified for histological subtype, phototype 1/2 and 3/4. Dose-response curves adjusted for age, age2, sex, phototype and non-occupational UV exposure were calculated. Results Participants with high versus no (OR 2.08; 95% CI 1.24–3.50; p = 0.006) or versus moderate (OR 2.05; 95% CI 1.15–3.65; p = 0.015) occupational UV exposure showed a more than two-fold significantly increased risk to develop BCC in commonly UV-exposed body sites. Multivariate regression analysis did not show an influence of phototype or histological subtype on risk estimates. The restriction of the analysis to BCC cases in commonly sun-exposed body sites did not influence the risk estimates. The occupational UV dosage leading to a 2-fold increased basal cell carcinoma risk was 6126 standard erythema doses. Conclusion The risk to develop basal cell carcinoma in highly occupationally UV-exposed skin was doubled consistently, independent of histological subtype, tumor localization and Fitzpatrick phototype.

BackgroundClinical registries may provide high-quality evidence on the use and effectiveness of therapeutic interventions under real-life conditions. Adults with moderate-to-severe atopic eczema (atopic dermatitis [AD]) are enrolled into TREATgermany and prospectively followed over at least 2years. This paper analyses the association between dermatological quality of life and work limitations.Materials and methodsTreatment modalities and abroad set of physician- and patient-reported outcome measures are documented using validated instruments to assess clinical disease severity (EASI [Eczema Area and Severity Index], objective SCORAD [objective-SCORing Atopic Dermatitis]), quality of life (DLQI [Dermatology Life Quality Index]), symptoms (POEM [Patient-oriented Eczema Measure]), global disease severity, as well as patient satisfaction and work limitations including presenteeism (WLQ [Work Limitation Questionnaire]). From 06/2016 until 12/2017, 241 individuals (mean age 43 +/- 15years, 38.6% female) were enrolled at 19recruitment centers; 69% of the patients were employed.ResultsEmployed persons had DLQI and WLQ scores of 10.6 +/- 6.9points and 17.7 +/- 18.1%, respectively. Mean presenteeism was substantial accounting for 9.2%. With coefficients of 0.39 and 0.33 WLQ and presenteeism scores significantly correlate with DLQI (p, Hintergrund Klinische Register tragen zur Evidenzbasierung der Gesundheitsversorgung und zur Umsetzung von Forschungsergebnissen in die Praxis bei. TREATgermany schließt Erwachsene mit moderater bis schwerer Neurodermitis („atopic dermatitis“ [AD]) mit prospektiver Beobachtung über mindestens 2 Jahre ein. Der Beitrag zeigt erste Ergebnisse zum Zusammenhang von krankheitsbezogener Lebensqualität und Leistungseinschränkungen im Beruf. Material und Methoden Dokumentiert werden objektive und subjektive Outcomes mit validierten Messinstrumenten: klinischer Schweregrad (EASI [Eczema Area and Severity Index], oSCORAD [objective-SCORing Atopic Dermatitis]), Lebensqualität (DLQI [Dermatology Life Quality Index]), Symptome (POEM [Patient-oriented Eczema Measure]), globaler Schweregrad (Investigator Global Assessment [IGA]/Patient Global Assessment [PGA]), Patientenzufriedenheit und berufsbezogene Leistungseinschränkungen (WLQ [Work Limitation Questionnaire]) inklusive Präsentismus (Produktivitätsverlust bei der Arbeit) sowie der Therapieverlauf. Von 06/2016 bis 12/2017 wurden 241 Patienten (Alter 43 ± 15 Jahre; 38,6 % Frauen) in deutschlandweit 19 Zentren eingeschlossen, 69 % waren berufstätig. Ergebnisse Erwerbstätige hatten DLQI- und WLQ-Mittelwerte von 10,6 ± 6,9 Punkten bzw. 17,7 ± 18,1 %. Der mittlere Präsentismus betrug 9,2 %. Mit r = 0,39 und 0,33 korrelierten die WLQ- und Präsentismus-Scores signifikant mit dem DLQI (p